Menu
Curie Logo
Faire un don
  • Accueil >
  • Publications >
  • Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

10 déc. 2019British Journal of Cancer

DOI : 10.1038/s41416-019-0619-y

Auteurs

Amélie Darlix, Guillaume Louvel, Julien Fraisse, William Jacot, Etienne Brain, Marc Debled, Marie Ange Mouret-Reynier, Anthony Goncalves, Florence Dalenc, Suzette Delaloge, Mario Campone, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Jean-David Fumet, Isabelle Lecouillard, Paul Cottu, Thierry Petit, Lionel Uwer, Christelle Jouannaud, Marianne Leheurteur, Véronique Dieras, Mathieu Robain, Michaël Chevrot, David Pasquier, Thomas Bachelot

Résumé

Abstract

Background

Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.

Methods

The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient’s prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan–Meier method).

Results

CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2−/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR− (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8–92.0). The median CNSM-FS was 10.8 months (95% CI: 16.5–17.9) among patients who developed CNS metastases. Molecular subtype was independently associated with CNSM-FS (HR = 3.45, 95% CI: 3.18–3.75, triple-negative and HER2−/HR+ tumours). After a 30-month follow-up, median OS after CNS metastasis diagnosis was 7.9 months (95% CI: 7.2–8.4). OS was independently associated with subtypes: median OS was 18.9 months (HR = 0.57, 95% CI: 0.50–0.64) for HER2+/HR+ , 13.1 months (HR = 0.72, 95% CI: 0.65–0.81) for HER2+/HR−, 4.4 months (HR = 1.55, 95% CI: 1.42–1.69) for triple-negative and 7.1 months for HER2−/HR+ patients (p <0.0001).

Conclusions

Tumour molecular subtypes strongly impact incidence, kinetics and prognosis of CNS metastases in MBC patients.

Clinical trial registration

NCT03275311.